Briacell Therapeutics Stock News

BriaCell Therapeutics (BCTX) announced on Thursday that the company was selected to perform a presentation on off-the-shelf cancer therapies at the American Association for Cancer

BriaCell Therapeutics Corp. (NASDAQ:BCTX) with the stream of 3.88% also noticed, India DigitalBridge Group, Inc. (NYSE:DBRG) encountered a rapid change of -1.36% in the last hour of Thursdays trading session. The post Active Stocks Momentum: BriaCell Therapeutics Corp. (NASDAQ:BCTX), DigitalBridge Group, Inc. (NYSE:DBRG) appeared first on Stocks Equity .

An investor agreed to buy 1.59 million shares, or 10% of its basic common shares

NEW YORK and VANCOUVER, British Columbia, Dec. 16, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces that certain members of its Board of Directors and Management team (the Insiders) have informed the Company of their intention, on an individual basis and not in concert, to use their personal funds to purchase approximately 10% of the Companys basic common shares outstanding.

The shares of Briacell Therapeutics Corp (NASDAQ:BTCX) are up 6.8% at $8.53 this morning, following the company's announcement that an insider intends to acquire up to 1.59 million shares, which repre

In the last trading session, 2.4 million shares of the BriaCell Therapeutics Corp. (NASDAQ:BCTX) were traded. Most recently the companys share price was $7.30, and it changed around -$0.6 or -7.59% from the last close, which brings the market valuation of the company to $104.63M. BCTX currently trades at a discount to its 52-week high BriaCell Therapeutics Corp. (NASDAQ: BCTX) Is Something To Consider Today. Read More »

The trading price of BriaCell Therapeutics Corp. (NASDAQ:BCTX) closed lower on Friday, December 10, closing at $7.90, -10.94% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

PALM BEACH, Fla. , Dec. 10, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer . Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints. These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the global triple-negative breast cancer treatment market revenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Overwhelming stocks: BriaCell Therapeutics Corp. (NASDAQ:BCTX -5.24%), The Williams Companies, Inc. (NYSE:WMB -3.69%) appeared first on Stocks Equity .

BriaCell Therapeutics Corp. (NASDAQ:BCTX) price on Wednesday, December 08, fall -0.64% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $9.36. A look at the stock’s price movement, the close in the last trading session was $9.42, moving within a range at $9.21 and $9.97. The beta value … A Stock Analysis Of BriaCell Therapeutics Corp.’s (BCTX) Read More »

NEW YORK and VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, presented clinical results from its lead clinical candidate Bria-IMT in a poster session held on December 8, 2021 during the 2021 San Antonio Breast Cancer Symposium ® (SABCS) (the Poster).

VANCOUVER, BC , Dec. 8, 2021 /PRNewswire/ -- USA News Group - Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit nearly $310 billion by 2030, according to Allied Analytics . Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis . Last December, biotechs working on breast cancer treatments saw their shares soar . This year has continued that momentum, with multiple biotech companies driving progress in the fight against cancer, including from Oncolytics Biotech Inc. (NASDAQ: ONCY ) (TSX: ONC ), Incyte Corporation (NASDAQ: INCY ), BriaCell Therapeutics Corp. (NASDAQ: BCTX ), Gilead Sciences, Inc. (NASDAQ: GILD ), and Eli Lilly and Company (NYSE: LLY ). Coming up between December 11-14, 2021 , Oncolytics Biotech Inc. (NASDAQ: ONCY ) (TSX: ONC ) will give an update at the upcoming 63 rd American Society of Hematology Annual Meeting and Exposition (ASH 2021) on its Phase II Triple-Negative Breast Cancer Trial—known as the IRENE study, which is evaluating the company''s flagship product pelareorep, an immunotherapeutic agent that turns "cold" tumors "hot", in combination with the anti-PD-1 checkpoint inhibitor, retifanlimab, from Incyte Corporation (NASDAQ: INCY ).

In the last trading session, 1.64 million shares of the BriaCell Therapeutics Corp. (NASDAQ:BCTX) were traded. Most recently the companys share price was $10.61, and it changed around $0.51 or 5.05% from the last close, which brings the market valuation of the company to $152.07M. BCTX currently trades at a discount to its 52-week high An Analysis Of BriaCell Therapeutics Corp. (NASDAQ: BCTX), And Its Business Forecast Read More »

BriaCell Therapeutics Corp. (NASDAQ:BCTX) saw a significant decrease in short interest in October. As of October 29th, there was short interest totalling 1,650,000 shares, a decrease of 14.9% from the October 14th total of 1,940,000 shares. Approximately 13.7% of the shares of the stock are sold short. Based on an average daily volume of 1,950,000 []

BriaCell Therapeutics (NASDAQ: BCTX) is one of 895 public companies in the Pharmaceutical preparations industry, but how does it compare to its rivals? We will compare BriaCell Therapeutics to related companies based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, risk, dividends and valuation. Risk and Volatility BriaCell Therapeutics has a beta []